Year archive

Simcere Pharmaceutical Group Limited — 2025 filings

All 73 regulatory filings released by Simcere Pharmaceutical Group Limited (S2P) in 2025, sourced directly from the official regulator.

73 Filings

2025 Period

2025 filings (73)

Filing	Released	Lang
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR SIM0610 (EGFR/cMET BISPECIFIC ANTIBODY-DRUG CONJUGATE) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2025-12-23	English
VOLUNTARY ANNOUNCEMENT - ENTERING INTO EXCLUSIVE LICENSING AGREEMENT WITH IPSEN IN RELATION TO SIM0613 (LRRC15 ANTIBODY-DRUG CONJUGATE) Regulatory Filings	2025-12-22	English
VOLUNTARY ANNOUNCEMENT - THE INCLUSION OF ENZESHU AND ENDOSTAR IN THE NEW NATIONAL REIMBURSEMENT DRUG LIST Regulatory Filings	2025-12-08	English
VOLUNTARY ANNOUNCEMENT - ENTERING INTO AN EXCLUSIVE LICENSE AGREEMENT WITH VIGONVITA FOR NEW INDICATIONS OF DEUTERATED REMDESIVIR HYDROBROMIDE Regulatory Filings	2025-12-03	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025 Regulatory Filings	2025-12-02	English
GRANT OF AWARDS UNDER THE 2021 RSU SCHEME Regulatory Filings	2025-12-01	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025 Regulatory Filings	2025-11-05	English
FURTHER REVISION OF THE 2025 AND 2026 ANNUAL CAPS OF EXCLUSIVE PROMOTION SERVICES COOPERATION AGREEMENT Regulatory Filings	2025-10-20	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025 Regulatory Filings	2025-10-08	English
NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED HOLDERS: NOTICE OF PUBLICATION OF INTERIM REPORT 2025 Report Publication Announcement	2025-09-29	English
NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS: NOTICE OF PUBLICATION OF INTERIM REPORT 2025 Report Publication Announcement	2025-09-29	English
2025 INTERIM REPORT Interim / Quarterly Report H1 2025	2025-09-29	English
SUPPLEMENTAL ANNOUNCEMENT REGARDING THE CONNECTED TRANSACTION IN RELATION TO THE ACQUISITIONS OF (1) ASSETS OF SANROAD SHANGHAI AND (2) ENTIRE EQUITY INTEREST IN XIANWEI M&A Activity	2025-09-18	English
Next Day Disclosure Return Share Issue/Capital Change	2025-09-10	English
COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE Capital/Financing Update	2025-09-10	English
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR SIM0609 (CDH17 ANTIBODY-DRUG CONJUGATE) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2025-09-08	English
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) OF DEUNOXAVIR MARBOXIL GRANULES WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2025-09-03	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2025 Share Issue/Capital Change	2025-09-03	English
PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE Share Issue/Capital Change	2025-09-02	English
CONNECTED TRANSACTION IN RELATION TO THE ACQUISITIONS OF (1) ASSETS OF SANROAD SHANGHAI AND (2) ENTIRE EQUITY INTEREST IN XIANWEI M&A Activity	2025-08-26	English
GRANT OF AWARDS UNDER THE 2021 RSU SCHEME Share Issue/Capital Change	2025-08-22	English
Terms of Reference of the Nomination Committee Governance Information	2025-08-21	English
VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE Transaction in Own Shares	2025-08-21	English
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2025 Interim / Quarterly Report H1 2025	2025-08-21	English
DATE OF BOARD MEETING Report Publication Announcement	2025-08-11	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025 Regulatory Filings	2025-08-06	English
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) OF RADEMIKIBART WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2025-07-08	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025 Regulatory Filings	2025-07-04	English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF ENZESHU IN CHINA BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2025-07-03	English
DISCLOSEABLE TRANSACTION - AMENDMENT TO THE LICENSE AGREEMENT WITH IDORSIA Regulatory Filings	2025-06-23	English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF QUVIVIQ IN CHINA BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2025-06-20	English
VOLUNTARY ANNOUNCEMENT - ENTERING INTO LICENSE AGREEMENT WITH NEXTCURE IN RELATION TO ADCs Regulatory Filings	2025-06-16	English
(UPDATED) FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2024 Notice of Dividend Amount	2025-06-13	English
(I) POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 13, 2025 AND (II) PAYMENT OF FINAL DIVIDEND Declaration of Voting Results & Voting Rights Announcements	2025-06-13	English
Next Day Disclosure Return Transaction in Own Shares	2025-06-09	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025 Regulatory Filings	2025-06-04	English
NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED HOLDERS: NOTICE OF PUBLICATION OF CIRCULAR AND NOTICE OF ANNUAL GENERAL MEETING Report Publication Announcement	2025-05-22	English
NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS: NOTICE OF PUBLICATION OF CIRCULAR, NOTICE OF ANNUAL GENERAL MEETING AND PROXY FORM Report Publication Announcement	2025-05-22	English
PROXY FORM FOR ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2025-05-22	English
NOTICE OF ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2025-05-22	English
(I) PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE AND TO REPURCHASE SHARES; (II) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (III) PROPOSED DECLARATION AND PAYMENT OF FINAL DIVIDEND; A Proxy Solicitation & Information Statement	2025-05-22	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2025 Regulatory Filings	2025-05-07	English
NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS: NOTICE OF PUBLICATION OF ANNUAL REPORT 2024 AND ENVIRONMENT, SOCIAL AND GOVERNANCE REPORT Report Publication Announcement	2025-04-28	English
NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS: NOTICE OF PUBLICATION OF ANNUAL REPORT 2024 AND ENVIRONMENT, SOCIAL AND GOVERNANCE REPORT Report Publication Announcement	2025-04-28	English
2024 ANNUAL REPORT Annual Report FY 2024	2025-04-28	English
2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Environmental & Social Information	2025-04-28	English
Next Day Disclosure Return Transaction in Own Shares	2025-04-16	English
Next Day Disclosure Return Transaction in Own Shares	2025-04-15	English
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR SIM0686 (FGFR2b ANTIBODY-DRUG CONJUGATE) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2025-04-10	English
Next Day Disclosure Return Transaction in Own Shares	2025-04-09	English
Next Day Disclosure Return Transaction in Own Shares	2025-04-07	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025 Share Issue/Capital Change	2025-04-03	English
GRANT OF AWARDS UNDER THE 2021 RSU SCHEME Share Issue/Capital Change	2025-03-25	English
FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2024 Notice of Dividend Amount	2025-03-24	English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024 Earnings Release FY 2024	2025-03-24	English
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) OF DEUNOXAVIR MARBOXIL TABLETS WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2025-03-17	English
DATE OF BOARD MEETING Regulatory Filings	2025-03-12	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025 Regulatory Filings	2025-03-05	English
PROFIT ALERT Earnings Release FY 2024	2025-02-21	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025 Regulatory Filings	2025-02-05	English
CONTINUING CONNECTED TRANSACTIONS (1) THE 2024 ANNUAL CAP BEING EXCEEDED AND (2) REVISION OF THE 2025 AND 2026 ANNUAL CAPS Regulatory Filings	2025-01-24	English
Next Day Disclosure Return Transaction in Own Shares	2025-01-23	English
Next Day Disclosure Return Transaction in Own Shares	2025-01-17	English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO RENEWAL OF CONTINUING CONNECTED TRANSACTIONS Regulatory Filings	2025-01-16	English
Next Day Disclosure Return Transaction in Own Shares	2025-01-16	English
Next Day Disclosure Return Transaction in Own Shares	2025-01-15	English
Next Day Disclosure Return Transaction in Own Shares	2025-01-14	English
VOLUNTARY ANNOUNCEMENT - OPTION TO LICENSE AGREEMENT OF SIM0500 WITH ABBVIE FOR RIGHTS OUTSIDE GREATER CHINA Regulatory Filings	2025-01-13	English
Next Day Disclosure Return Transaction in Own Shares	2025-01-08	English
Next Day Disclosure Return Transaction in Own Shares	2025-01-07	English
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR SIM0505 (CDH6 ANTIBODY-DRUG CONJUGATE) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2025-01-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024 Regulatory Filings	2025-01-03	English
Next Day Disclosure Return Transaction in Own Shares	2025-01-02	English